A multicentre open label non comparative phase II trial to evaluate the efficacy and safety of ZD1839 (Iressa) alone as first line treatment in patients with er-negative metastatic breast cancer
Study identifier:1839IL/0083
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A multicentre open label non comparative phase II trial to evaluate the efficacy and safety of ZD1839 (Iressa) alone as first line treatment in patients with er-negative metastatic breast cancer
Medical condition
Breast Cancer
Phase
Phase 2
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jun 2002
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
